NCT01161836View on ClinicalTrials.gov

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

PHASE1CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

June 30, 2011

Conditions

Advanced Solid Tumors

Interventions

DRUG

Iniparib

"Solution for infusion~60-minute intravenous infusion"

Trial Locations (1)

98405

Northwest Medical Specialties, Tacoma

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY